National Institutes of Neurological Disorders and Stroke

Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and in Health Disparities Populations

Identified in the Alzheimer’s Disease-Related Dementias Summit 2016 there unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States, including in health disparities populations, when a patient, relative, or care provider indicates concern. To this end the NINDS initiated a consortium with the goal of developing simple, quick clinical paradigms to administer in a primary care clinical setting to Detecting Cognitive Impairment, Including Dementia. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Program Staff

Roderick Corriveau, Scientific Program Director

Claudia Moy, Administrative Program Director

Jordan Gladman, Health Program Special


Roderick Corriveau, PhD

Program Director, Neurodegeneration

Division of Neuroscience

National Institutes of Neurological Disorders and Stroke

Dr. Rod Corriveau joined the NINDS as a Program Director in 2010 and is responsible for the NINDS Alzheimer’s disease and vascular contributions to cognitive impairment and dementia (VCID) portfolios. In addition to his role in DetectCID, Rod is the Scientific Project Officer for the MarkVCID consortium, which is validating small vessel VCID biomarkers to readiness for large scale clinical trials. Rod is also the NIH Program lead for Alzheimer’s Disease-Related Dementias (ADRD) Summits (2013, 2016, and with planning underway for 2019). These meetings are responsive to the National Plan to Address Alzheimer’s Disease and have set or will revise national priorities to guide research in the Alzheimer’s-related dementias through 2025. Dr. Corriveau received his bachelor’s degree in biochemistry from Simon Fraser University, and his Ph.D. in Neurosciences from the University of California San Diego. His graduate and postdoctoral studies focused on gene expression and the role of electrical activity in neural circuit development. As an HHMI Postdoctoral Associate with Carla Shatz at UC Berkeley, he contributed to the discovery of a role for immune molecules in synaptic development and change. Dr. Corriveau was an Assistant Professor at the LSU Health Sciences Center where he investigated the role of NMDA receptor-dependent neural signaling in gene expression and naturally occurring neuronal cell death. Prior to joining NINDS, he was an Associate Professor at the Coriell Institute for Medical Research.

Claudia Moy, PhD

Program Director

Division of Clinical Research

National Institutes of Neurological Disorders and Stroke

Dr. Moy is an epidemiologist with an interest in clinical trials methods as well as outcome measures, particularly patient-centered outcomes. She holds a doctorate in epidemiology from the University of Pittsburgh and a Master of Public Health degree from the Johns Hopkins University. Her prior experience includes a postdoctoral position in epidemiology at the University of Pittsburgh and a faculty position at the Johns Hopkins University school of medicine, where she was involved in the design, conduct and monitoring of multicenter clinical trials.


Jordan T. Gladman, PhD

Health Program Specialist

Division of Neuroscience

National Institutes of Neurological Disorders and Stroke

Dr. Gladman has a broad skill set in basic, clinical, and translational research from his time at The Ohio State University and the University of Virginia where he researched the molecular mechanism underlying muscular atrophy (SMA), myotonic dystrophy type 1 (DM1). At the National Institute of Neurological Disorders and Stroke he provides key coordination and support for the NINDS/NIH Alzheimer's Disease-Related Dementias (ADRD) extramural research program. The NINDS ADRD program is responsive to the National Plan to Address Alzheimer's disease and includes research on the Alzheimer's-related dementias as defined by the National Plan (frontotemporal, Lewy body, vascular and mixed dementias).